[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100528768":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":25,"centralContacts":42,"locations":48,"responsibleParty":66,"collaborators":25,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":25,"eligibilityCriteria":74,"healthyVolunteers":71,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":25,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":25,"overallStatus":51,"whyStopped":25,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Navamindradhiraj University","OTHER",[8,15,21],{"label":9,"type":10,"description":11,"interventionNames":12},"Antiplatelet drug","ACTIVE_COMPARATOR","In this study, antiplatelet drugs are medications that patients take to treat their underlying condition, such as aspirin 81 mg\u002Fday or clopidogrel 75 mg\u002Fday.",[13,14],"Drug: Aspirin 81Mg Ec Tab","Drug: Clopidogrel",{"label":16,"type":17,"description":18,"interventionNames":19},"Antiplatelet drug with antioxidant","EXPERIMENTAL","Antiplatelet drugs are medications that patients take to treat their underlying condition, such as aspirin 81 mg\u002Fday or clopidogrel 75 mg\u002Fday combined with N-acetylcysteine 600 mg\u002Fday.",[13,14,20],"Drug: N-acetylcysteine",{"label":22,"type":23,"description":24,"interventionNames":25},"No medication","NO_INTERVENTION","Patient with no medication used.",null,[27,32,36],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":25},"DRUG","Aspirin 81Mg Ec Tab","Patients take aspirin 81 mg per day.",[9,16],{"type":28,"name":33,"description":34,"armGroupLabels":35,"otherNames":25},"Clopidogrel","Patients take clopidogrel 75 mg per day.",[9,16],{"type":28,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"N-acetylcysteine","Patients are given N-acetylcysteine 600 mg per day.",[16],[41],"NAC-long",[43],{"name":44,"role":45,"phone":46,"phoneExt":25,"email":47},"Yolradee Winuntamalakul","CONTACT","+66851283362","yolradee.win@nmu.ac.th",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Department of ophthalmology, Faculty of medicine, Vajira hospital, Navamindradhiraj University","RECRUITING","Bangkok","Dusit","10300","Thailand","TH",{"type":58,"coordinates":59},"Point",[60,61],100.50144,13.75398,{"lat":61,"lon":60},[64],{"name":44,"role":45,"phone":65,"phoneExt":25,"email":47},"+6622443874",{"type":67,"investigatorFullName":44,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Principal Investigator","100528768","phase-3-effects-of-antiplatelet-and-antioxidant-agents-on-drusen-progression-a-pilot-prospective-cohort-study-100528768",false,"NCT06165068","Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study","Inclusion Criteria:\n\n* Dry AMD with at least 1 large drusen. According to the AREDS study, large drusen have a size of more than 125 micron.\n* Patients can evaluate SD-OCT (Spectral domain optical coherence tomography), OCT angiography, and best-corrected visual acuity.\n* Age range: 50-85 years\n* Patients who have previously used antiplatelet drugs.\n\nExclusion Criteria:\n\n* Patient with advanced AMD, such as geographic atrophy, neovascular complications (choroidal neovascularization)\n* Patient with additional retinal diseases that affect visual acuity, e.g., retinal detachment, diabetic macular edema.\n* Patient with a history of intravitreal anti-VEGF injection or macular laser.\n* Patient using SSRIs, SNRIs, azole, NSAIDs, dual antiplatelet, anticoagulant medications.","ALL","50 Years","85 Years",{"count":79,"type":80},174,"ESTIMATED","INTERVENTIONAL",[83],"PHASE3","The aim of this clinical trial is to evaluate the effect of low doses of antiplatelet medications (aspirin 81 mg\u002Fday or clopidogrel 75 mg\u002Fday) with or without a combination of antioxidants (N-acetylcysteine 600 mg\u002Fday) in a dry AMD patient with large drusen.\n\nParticipants will divided in to three groups.\n\n* Participants who were already taking low dose antiplatelet medications.\n* Participants who take the antiplatelet drug mentioned above in addition to the antioxidant prescribed by the investigator\n* Participants does not use any medications.",[86],"Dry Age-related Macular Degeneration","2023-12-11",{"date":89,"type":90},"2023-12-15","ACTUAL",{"date":92,"type":80},"2023-12",{"date":94,"type":80},"2026-09",{"name":5,"class":6},1]